![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
An Australian biotech company is already turning heads so far on Wednesday after it was announced results from its GBM-AGILE, which is a phase II/III study that included an To read the full story...
Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma PR Newswire SYDNEY, July 10, 2024 GBM AGILE trial data shows clinically meaningful improvement in a...
KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER PR Newswire SYDNEY, June 27, 2024 SYDNEY, June 27, 2024 /PRNewswire/ -- Kazia Therapeutics...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0.3 | 50 | 0.6 | 1.03 | 0.44 | 43128 | 0.72655185 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions